Abernethy’s Departure From US FDA Gives Next Commissioner Options For A New Number Two

Janet Woodcock has been in the lead in the commissioner race for months without an announcement, but now serious doubts are being cast on her candidacy, including the tone of remarks at a White House press briefing.

THE QUESTION OF WHO WILL BE THE US FDA’S NUMBER TWO IS STARTING TO LOOM ALMOST AS LARGE AS WHO WILL BE THE COMMISSIONER.

The imminent departure of US Food & Drug Administration Principal Deputy Commissioner Amy Abernethy is clearly a loss of leadership for an agency already living through an uncertain transition period, but does leave open the ability for the next commissioner (whether it is Acting Commissioner Janet Woodcook or another nominee) to choose a number two that reflects that individual’s priorities.

Woodcock announced Abernethy’s intention to leave FDA in a 23 March email to staff. In an interview...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

CAR-T REMS Removal Should Boost Access, But Long-Term Follow-Up, Black Box Remain

 

The REMS removal and labeling changes should open up CAR-T treatment to many more US patients, although other regulatory hurdles and safety language that experts had wanted removed still stand.

PDUFA VIII: Cutting Perceived Conflict Of Interest May Be A Theme

 

Ongoing questions about user fees exerting too much influence over the FDA could spawn a shift in the PDUFA structure when talks begin later this year.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By 

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

More from Agency Leadership

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

Quotable: Top Experts On Policy Hot Topics

 

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By 

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.